Ropes & Gray Advises CANbridge Pharmaceuticals in Exclusive Worldwide License Agreement with UMass Chan Medical School
Ropes & Gray represented CANbridge Pharmaceuticals, a China-based biopharmaceutical company, in its exclusive worldwide license agreement with UMass Chan Medical School relating to the development and commercialization of a novel second-generation gene therapy for treatment of spinal muscular atrophy. The agreement was announced on January 4.
The CANbridge Pharmaceuticals team was led by IP transactions partner David McIntosh and associate Sameer Desai.